MetiMedi Pharmaceuticals

Developing Unique Platform Technology
For Unmet Needs for Cancer Therapies and Beyond


MetiMedi Pharmaceuticals


Our People

  • Management Team
  • Scientific Advisory Board
  • Hwan Mook Kim




  • Eun-Hee Ji


  • Chong Hwan Chang


  • Hyunseo Koo

    (Patent Attorney/Director)

  • Keele Park


  • Jong-Won Rhie

    (MD. Ph.D.)

  • Jeong-Heum Baek

    (MD. Ph.D.)

  • Elizabeth S. Song


  • Sang-Bae Han


  • Seung Hyun Oh

    (Ph.D. D.V.M. DKCLAM)

  • Kwagng Won Jeong



Cell Metabolic Reprogramming Platform (CMRP)
  • “ Tumors cells and effector T cells share dependencies for glucose, glutamine, tryptophan, or arginine.

  • a

    Tumor cells, by their extensive need of glucose, glutamine, tryptophan of arginine will impoverish the tumor area. This resource consumption from tumor cells will directly impact CD8 T cell metabolism leading to exhausted phenotype and indirectly, through metabolite secretion like for example lactate, stimulate the development of an immunosuppressive tumor micro-environment.
  • b

    At the opposite, if tumor cells have moderate metabolic demand, due to intrinsic characteristics or therapeutic manipulations, a fully functional anti-tumor immune response will mediated tumor elimination.”

Ref: Modified from Cerezo and Rocchi, Nature (2020) 11:964


Big Picture of MetiMedi Pharmaceuticals


  • · CRC : Colorectal cancer
  • · NASH : Non-alcoholic steatohepatitis
  • · RA : Rheumatoid arthritis
  • · AMD : Age-related macular degeneration

  • · AD : Alzheimer’s disease
  • · PD : Parkinson's disease
  • · MS : Multiple sclerosis
  • · IPF : Idiopathic pulmonary fibrosis


  • Status of Clinical trials



    Phase 2 clinical trial of Metimedi Pharmaceutical Co., Ltd.'s anti-cancer

    drug OMT-111(Pre-filled Syringe Formulation) was successfully processed as

    planned, and the last patient is currently on investigation.

    As soon as the last patient administration is completed, Phase 2 trial will be

    completed and reported to the Ministry of Food and Drug Satety of Korea after

    thorough clinical result analysis.

    In addition, Metimedi is planning to write a journal paper about the clinical trials

    and present to the global conference in the future. It will promote marketing

    activities for global pharmmaceutical companies.

    OMT-111 is further developed as an active tablet form named as Meti-101.

    Meti-101 will improve the patient's convenience of taking medicines and is applicable

    for various purposes.

    On Apr. 21, 2022, clinical 1b/2a trials of Meti-101 was approved by the Ministry of

    Food and Drug Safety of the Republic of Korea.

    On Aug. 11, 2022, Meti-101 was conditionally approved for the first IRB at

    Gachon University Gil Hospital. It is expected to receive final approval after

    submitting the documents requested by Gil Hospital.

    Once the final IRB is approved, the clinical trial contract will be singed and initiate

    the trial on registered 30 patients.

  • Chronic Inflammatory Diseases(CID) Patent Registrati...



    Metimedi Pharmaceutical Co., Ltd.'s CID (Chronic Inflammatory Disease) patent

    has been divided into three in the United States, and patent registration is under


    On Aug. 25, 2020, Metimedi's patents for multiple sclerosis, age-related macular

    degeneration, and non-alconholic steatohepatitis (NASH) were passed the U.S.

    Patent Office review and successfully registered in the U.S.

    Moreover, on Jan. 26, 2021, Metimedi gained the approval of its patent for

    Alzheimer's disease, Parkinson's disease, atherosclerosis, and inflammatory bowl

    dlsease in the U.S. Patent Office.

    Metimedi is planning to get more patents on other chronic inflammatory diseases.

  • Formulation Patent Registration Status



    On July. 7, 2022, the formulation patent for the anti-cancer drug of Metimedi

    Pharmaceutical Co., Ltd. was successfully registered in Mexico after passing the

    the patent registration by the Mexico Patent Office.

    As a result, Metimedi's anti-cancer drug formulation patent has been registered

    in two countries, the United States (registered March, 29, 2022) and Mexico.

    Currently,Metimedi is on the process of expanding its formulation patent further

    in 13 countries including European Patent Convention, Taiwan, and Japan.

  • 정기주주총회 소집공고(Announcement of the convening ...



  • 항암제 임상시험 진행 현황(Status of Clinical trials)



    (주)메티메디제약의 항암제 OMT-111(프리필드 실른지 제형)의 임상2상은

    계획대로 잘 진행되어 현재 마지막 환자 투약이 진행되고 있습니다.

    마지막 환자 투약이 종료되는대로 통계처리 후 식약처에 완료 보고할 예정입니다.

    또한 임상2상 결과에 대한 논문을 작성하여 학회에 발표하고, 글로벌 제약사들을 상대로한 본격적인 마케팅 활동을  추진할 예정입니다.

    한편 (주)메티메디제약의 항암제 OMT-111을  환자의 복용 편의성을 높이고 다양한 용도로 사용할 목적으로 개발한 경구제(장용캡슐)인

    Meti-101의  임상1b/2a 시험은  지난 2022년 4월 21일 대한민국 식약처의 IND 승인을 받았고, 8월 11일 가천대 길병원에서 1차 IRB 결과

    조건부 승인을 받았습니다.  길병원 측이 요청한 몇가지 자료를 제출하면 최종 승인을 받을 것으로 예상됩니다.

    최종 IRB 승인 즉시 임상시험 계약을 체결하고 총 30명 예정의 임상시험에 착수할 예정입니다. 

  • CID 특허 등록 현황(Chronic Inflammatory Diseases Pat...



    (주)메티메디제약의 CID(Chronic Inflammatory Diseases) 특허는 미국에서 3개로 분할되어  특허 등록 심사가 진행되고 있습니다.

    2020년 8월 25일에 multiple sclerosis, age-related macular degeneration, nonalcoholic steatohepatitis(NASH)

    에 대한 심사가 통과되어 특허가 등록되었습니다.

    계속해서 2021년 1월 26일에 Alzheimer's disease, Parkinson's disease, atherosclerosis, inflammatory bowel disease

    에 대한 심사가 통과되어 특허가 등록되었습니다.

    현재 나머지 다른 CID 질병에 대한 특허 등록 심사가 진행되고 있습니다.


Contact us

경기 의왕시 이미로 40 (인덕원IT밸리) D동 701

Eun-Hee Ji, Ph.D.

Chief Technology Officer

Phone  +82-32-205-0541


Heeyeol Yeom

Manager, Business Development

Phone  +82-32-205-0541